Brain-derived neurotrophic factor (BDNF) has been studied extensively in relation to the susceptibility to mood disorders (MD), although it remains to be clarified whether BDNF is a susceptibility locus for MD phenotypes, including therapeutic response to antidepressants. We have performed a single-marker and haplotype association study of eight TagSNPs polymorphisms in the genomic region containing the BDNF gene in 342 control subjects and 374 patients with MD, and have tested the association with antidepressant treatment outcome. None of the eight single nucleotide polymorphisms (TagSNPs) was significantly associated with MD phenotype after Bonferroni correction. In the single-marker analysis, a SNP was found to be associated with the patient's state of 'remitter' after adequate trial with a single antidepressant phenotype (odds ratio (OR) ¼ 2.95; P ¼ 0.0025). We also identified a haplotype associated with this phenotype. This study supports the implication of BDNF in antidepressant treatment outcome in MD, with specific association with 5 0 upstream region of BDNF gene.
Introduction
Mood disorders (MD) such as major depression disorder (MDD) and bipolar disorder (BD) are common, severe and chronic psychiatric diseases, often causing disability, significant functional impairment and are sometimes life-threatening. In fact, these disorders are among the leading causes of disability worldwide. 1 Antidepressant pharmacotherapy is an essential treatment option for major depressive episodes, but unfortunately at least one-third of patients who complete an adequate trial of an approved antidepressant do not show an acceptable response. 2 Thus, drug resistance remains to be a source of morbidity and mortality for patients with MD. Several factors that may contribute, both individually and in combination, to antidepressant treatment response have been reported: patient non-adherence, misdiagnosis, suboptimal treatments, sex, age at onset of illness, number of prior episodes, severity of depression, major depressive episodes with psychotic features, bipolar or unipolar depression and a range of comorbid conditions (psychiatric, personality, general medical disorders, vascular risk factors (VRF) and structural brain changes like deep white matter disease). [2] [3] [4] [5] [6] In addition, genetic factors are believed to play a major role in response to antidepressants and a bulk of pharmacogenetic studies is available nowadays. One of the most studied genes has been the 5-hydroxytryptamine transporter (SLC6A4), which has been involved in the mechanism of action of many antidepressant drugs. Independent studies have reported that patients carrying the long variant of the in/ del polymorphism of the upstream regulatory region of the SLC6A4 gene show better response to selective serotonin reuptake inhibitors (SSRIs) (reviewed in 7 ). Other genes encoding for serotonergic and noradrenergic pathways, glucocorticoid receptors and drug metabolizing enzymes have also been reported to be associated to the antidepressant response. 8 Depressive disorders are considered complex genetic traits, which are either polygenic or multifactorial, with multiple genes interacting with the environment. In spite of notable advances in this field, and several genes having been involved in the development of the disorder, the molecular mechanisms underlying the susceptibility to depression remain unrevealed (reviewed in 9 ). Recent evidence has suggested that impairment of neuroplasticity and cellular resilience might underlie the pathophysiology of MDD and some antidepressant treatments might exert major effects on signalling pathways that regulate neuroplasticity and cell survival. This has taken shape as the formulation of a neurotrophic hypothesis of depression, stating that reduction of brain-derived neurotrophic factor (BDNF) levels increase vulnerability to depression. 10 BDNF pertains to neurotrophins, a family of closely related peptides that also include nerve growth factor (NGF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/ 5). 11, 12 This neurotrophin provides trophic support to cholinergic, dopaminergic and 5-hydroxytryptamine containing neurons [13] [14] [15] [16] and is widely distributed in the central nervous system (CNS), including hippocampus, neocortex, amygdala, cerebellum and hypothalamus, key regions in the regulation of mood and behavior.
The human BDNF gene maps to human chromosome 11p13 17 and is composed of six 5 0 exons that are differentially spliced to a single 3 0 terminal exon (exon 7) that encodes the entire sequence of mature BDNF (GenBank accession AF411339). Several partial mRNAs that have been sequenced indicate that the transcriptional regulation of BDNF is complex and involves the use of alternative promoters, alternative splice donor and acceptor sites that produce between-and within-exon patterns of alternative splicing, and the use of alternative polyadenylation sites. 18 At the biochemical level, the first evidence of a possible involvement of BDNF in MD came from an initial report of reduced serum BDNF in depressed patients, 19 which has been repeatedly confirmed by independent studies that also found that protein levels revert to normality after antidepressant treatment. [20] [21] [22] [23] [24] [25] Recently, decreased serum BDNF levels have also been reported in BD during depressive and manic episodes. 26 At the molecular level, the studies of the role of BDNF in MD have encompassed different genetic variants located along the BDNF genomic region and have used different approaches, using case-control or family-based association studies, but no conclusive results have been achieved. Among all variants, the most studied one is a single nucleotide polymorphism (SNP), G to A transition at nucleotide 196, that results in a Val66-to-Met (V66M; 11350.0002; dbSNP rs6265) change, which is located in the 5 0 pro-BDNF sequence. In the case of BD, two initial and independent family-based reports found evidence of haplotypes containing rs6265 associated to the disorder. 27, 28 These results have been replicated in trios of children with prepubertal BD 29 and in an additional case-control study performed on adults. 30 Very recently, a functional polymorphic region near the translation initiation site has also been found to be associated to BD. 31 In spite of this evidence, other investigators have not been able to replicate these findings in case-control association studies. [32] [33] [34] [35] [36] [37] [38] In the case of MDD, some studies reported a negative association of the Val66Met BDNF polymorphism, 33, 39, 40 while other studies have found a haplotype containing this variant to be positively associated to the MDD phenotype. 41, 42 Moreover, positive associations of this single SNP and a haplotype containing it have been reported to be associated to childhood-onset mood disorder 41, 43 as well as geriatric depression. 44 Studies on animal models provide a strong support for the hypothesis that BDNF contributes to the therapeutic action of antidepressants and electroconvulsive therapy (ECT). Both antidepressants and ECT increase the expression and signalling of BDNF in the hippocampus and cortex, [45] [46] [47] [48] [49] [50] and the injection of BDNF into the brain or overexpression of its receptors in transgenic mice produces similar behavioral responses to those typically observed after treatment with antidepressant drugs. 51, 52 Moreover, it has recently been reported that the loss of BDNF in forebrain regions in conditional BDNF knockout mice attenuates antidepressant efficacy. 53 Despite the large bulk of data collected regarding the involvement of BDNF in MD, there is little information on the role of BDNF variants in the response of MD to antidepressant treatments. To our knowledge, two studies in Asian population have assessed the relationship between Val66Met polymorphism and antidepressant response in MDD, reporting no association but a trend to improve 4-week fluoxetine antidepressant response for heterozygous patients in one study 39 and association with citalopram efficacy, with M-allele carriers responding better to 8-week citalopram treatment 54 in the other. To shed light upon this issue, we performed a genetic case-control study for this candidate gene, including 342 control subjects and 374 patients with MD. We genotyped a set of eight tagging single nucleotide polymorphisms (TagSNPs) polymorphisms representative of the patterns of common variation identified in European population in the genomic region containing the BDNF gene. As BDNF has been involved in the therapeutic action of antidepressants, we further tested the hypotheses that variants in human BDNF gene may be related to antidepressant treatment outcome in major depressive episodes, taking into account other clinical factors that may influence this trait.
Results

Population stratification
We tested the case-control sets for population stratification as described in Materials and methods. The set of anonymous unlinked markers showed no evidence of stratification, since allelic frequencies were similar and the best solution for each sample was a single population.
BDNF single-SNP association analyses
We performed a case-control study with TagSNPs covering the entire BDNF genomic region. We genotyped the eight selected TagSNPs in 374 Spanish adults recruited as MD patients and 342 controls. Demographics and clinical characteristics are provided in Table 1 .
Complete genotypes were available for 98.4% of MD patients and 95.5% of control subjects. Genotypes for all SNPs were consistent with Hardy-Weinberg equilibrium (HWE; Po0.01 by w 2 ) in control subjects. Genotype and allele frequencies are provided in Table 2 .
The frequencies of the single-locus case-control association analysis for the eight SNPs showed that only SNP rs908867 was moderately associated to MD phenotype adjusted by covariate sex (P ¼ 0.02). As TagSNPs may also be seen as a set of relatively independent markers, we applied Bonferroni correction for eight independent tests and the rs908867 association did not remain significant.
In addition, we performed single-locus case-control exploratory analysis, considering unipolar and bipolar depressives separately without detecting significant association with BDNF genotypes (data not shown); likewise, patients with recurrent depressive disorder and single depressive episode have been analyzed separately, and we have not detected significant association with any of the TagSNPs (data not shown); due to the exploratory nature of the latter two analyses, we have not included them in the correction for multiple comparisons.
As antidepressant drugs and ECT have been consistently seen to regulate BDNF transcription levels, we further investigated the association of this modestly positive SNP (rs908867) with the patient's state of 'remitter' vs 'nonremitter' after adequate trial with a single antidepressant treatment. The non-adjusted association study revealed significant values for all except the recessive model of inheritance out of the five genetic models tested, the additive model being the one that best fit the data. Thus, patients heterozygous for the A allele have almost three-fold probabilities of achieving clinical complete remission and almost six-fold if they are homozygous (odds ratio (OR) ¼ 2.95; confidence interval (CI) 95% ¼ 1.48-5.88; P ¼ 0.0152). The model adjusted by clinical covariates remained significant for all models of inheritance tested, except for the recessive model. Again, the additive model was the strongest one (OR ¼ 2.95; CI 95% ¼ 1.48-5.88; P ¼ 0.0025) ( Table 3) . We also tested, in an exploratory manner, the functional SNP rs6265 with this phenotype to replicate the previous findings of other studies. 39 , 54 We could not find a significant involvement of this variant in treatment outcome (data not shown).
BDNF haplotype association study
We could not find evidence that a common BDNF TagSNPs haplotype was associated with MD (data not shown). We further studied the same phenotype that yielded positive Severity of index episode for the study.
BDNF and antidepressant outcome in mood disorders
M Gratacòs et al results in the single-SNP association analysis ('remitters' vs 'non-remitters'). The eight TagSNPs resolved seven haplotypes occurring at frequencies of 1% or more. The overall distribution of haplotypes was not significantly different between treatment 'remitters' vs 'non-remitters' (data not shown). To refine the haplotype construction and to identify a potential causative core region, we used an unbiased sliding window method to construct successive and adjacent haplotypes across BDNF in windows of two, three and four adjacent SNPs. The results from the sliding window analyses revealed significant two, three and four marker haplotypes, which exceeded the significance levels of the individual markers (Supplementary Table 1) , and implicated SNPs rs12273363, rs908867 and rs1491850. We further computed the regression of the antidepressant treatment outcome phenotype on haplotype combination Table 4 ). The variant that we found significantly associated to the phenotype (rs908867) is located 2.2 kb from a C to A transversion occurring 281 bp upstream of the proposed transcription start site for exon 1. The low-activity À281A allele of this SNP has been shown to be protective against anxiety and psychiatric morbidity. 55 Since this SNP was not genotyped in the HapMap project, it was not considered in the selection of TagSNPs, but due to both its functional effect and proximity to our associated SNP, we performed a pyrosequencing assay to genotype this variant (rs28383487) and reanalyzed our data. The frequency of the rare allele was 0.8, which is higher than the 0.03 previously reported in Caucasian population. We could not find any evidence of association in the single-SNP analyses neither by considering MD phenotype (P ¼ 0.4) nor by considering remitters vs non-remitters phenotype (P ¼ 0.1). With respect to the haplotype analyses, the significant window after reanalysis was again the one containing the three previous SNPs rs12273363, rs908867 and rs1491850 (data not shown).
Finally, to test the likelihood that results will replicate, we used a 'bootstrap' strategy and the stability of results across numerous configurations of the subjects was examined. Following 300 bootstrap data sets generated from the original sample, rs908867 was selected (statistically significant at Bonferroni significant level) with the highest frequency (242 out of 300).
Discussion
The first finding of this study is that none of the eight TagSNPs, including the Val66Met functional variant, was significantly associated with the MD phenotype. Indeed, the overall distribution of haplotypes was not significantly different between cases and controls. This is in accordance with previous reports that have not been able to detect a positive association of BDNF with BD or MDD patients. [32] [33] [34] [35] [36] [37] [38] [39] [40] It is interesting to note that the studies that have reported positive associations with MD have recruited patients with a high genetic component, such as positive family history of affective disorder 30 or early onset of the disease. 29, 41, 43 Furthermore, controversial results could also be explained by other factors such as ethnicity-dependent effects, lack of statistical power due to limited sample sizes or clinical heterogeneity.
The major finding of this study is that one SNP located in the BDNF 5 0 upstream region is strongly associated with a phenotype consisting of achieving complete clinical remission of a major depressive episode after an adequate trial with a single antidepressant. Two studies in Asian population have assessed the association of a BDNF gene variant (Val66Met; rs6265) and therapeutic response to antidepressants. One reported a trend but did not find evidence for a significant association, 39 and the other found an association with citalopram efficacy. 54 Differences in the allelic frequencies for the BDNF Val66Met polymorphism between populations of different ethnic origins have previously been reported; 56 likewise, ethnic differences in the distribution of genetic polymorphisms are very common and have been known in the pharmacogenetics field, affecting genes coding for drug metabolizing enzymes, targets, receptors and transporters. 57 It is quite likely, according to our results, that the Val66Met variant is not directly related to this phenotype in Caucasian population, and that genotyping of additional variants near the 5 0 end of the gene would have led to the detection of the association with the rs908867 SNP reported here in Caucasian population. With respect to this associated SNP, two ideas make it unlikely that it has a functional effect. On one hand, the non-variant nucleotide (G) in human sequence is conserved neither in rat nor in mouse. On the other hand, rs908867 is located 229 bp upstream from the transcription starting site of exon 1. Taking into account that the putative promoter for exon 1 is located about 500 bp upstream the initiation starting site, 58, 59 it is not likely that this SNP has direct functional consequences. In spite of this, and to partially answer this question, we used an interactive web-based SNP analysis tool (http://pupasuite.bioinfo.cipf.es) to predict if the change disrupts potential transcription binding sites. The program did not predict that the rs908867 site lies within any of these motifs and is not considered to have a putative phenotypic effect in the expression of the gene, thus indicating that this variant is representative of the region and actually correlated with the true functional variant. In this line, we genotyped an SNP upstream from the proposed transcription start site for exon 1, or in BDNF promoter that has been shown to decrease the transcriptional activity of the gene. 55 We could not find any evidence of association to this SNP, which indicates that another yet unknown causative variant in the region must be correlated with the phenotype. We have also identified a haplotype associated to this particular phenotype (TAT) using a sliding window approach, which evidences an association in a region between rs12273363, rs908867 and rs1491850, spanning 4.8 kb, and pointing out a region located at 1.56 and 1 kb from the BDNF non-coding exons 1 and 2, respectively.
We must consider that haplotype frequency estimation is always prone to error, and as we had to infer haplotypes because of phase uncertainty, those are not true haplotypes. First, the use of TagSNPs is a useful approach to reduce the number of variants to be genotyped, but as we choose to study the most polymorphic markers, those variants that have an infrequent allele are discarded, whereas they may be in fact the functional ones. Second, in spite of the fact that exclusion of haplotypes at low frequency substantially reduces the probability of false positives, missing haplotypes are more probable for rare SNP alleles and thus we cannot exclude that functional mutations in rarer haplotypes are associated with this phenotype.
We are aware that the extent of the region that the haplotype points out is not a cutting edge. The genomic region of BDNF is composed of two linkage disequilibrium (LD) blocks. SNPs contained in the window significant showing association are in tight LD with other SNPs. These include the functional Val66Met variant and a microsatellite polymorphism located approximately 1 kb upstream from the translation initiation site of BDNF, which has been recently demonstrated to affect transcriptional activity. 31 When markers are in perfect LD, there is no statistical means to distinguish which marker is the true functional one. In spite of this, the sliding window resembles fine disease mapping methods, because partial haplotypes are more accurately predicted by most algorithms and give a quantitative suggestion of the signal observed in the background. Thus, it has better power to detect association between disease and short haplotypes than whole-region haplotypes. Hence, according to our results, the region putatively involved in therapy response seems to be narrow and located in the 5 0 region of the gene. How the identified haplotype in the 5 0 region of BDNF can correlate with decreased functional activity of BDNF, possibly through an altered transcription from BDNF promoter 1, and thus potentially affecting the expression of pro-BDNF, remains to be clarified. Resequencing of the 5 0 BDNF region would be necessary to untangle the genetic substrate for the phenotype of antidepressant treatment outcome.
Recent hypotheses have implicated BDNF in the response to antidepressant treatment. The time lag for the therapeutic response has led to the suggestion that cellular adaptations to the acute actions of antidepressants can occur at many levels such as regulation of neurotransmitter receptors, signal transduction cascades and gene transcription. 60 Previous studies have reported that chronic treatment with major classes of antidepressants increases the expression of BDNF in rat brain structures belonging to the meso-cortico-limbic pathway and neurogenesis in adult hippocampus; [61] [62] [63] Interestingly, these brain regions may be critical for mood regulation. 64 The result of our study adds to a growing body of data that suggest that BDNF exerts antidepressant activity. This view is strongly supported by a recent report of antidepressant efficacy diminished in conditional BDNF knockout mice. 53 Thus, our findings could indirectly indicate that the role of BDNF in the efficacy of antidepressants would be facilitated in those individuals carrying the TAT haplotype.
Nevertheless, due to complexity of MD, variants in a single gene are unlikely to be responsible for the wide variability seen in drug response. It has been shown that the expression of BDNF could be affected by disturbances in cortisol production. 65 Hyperactivity of the hypothalamicpituitary-adrenal axis, with elevated secretion of corticotrophin releasing factor, and subsequently cortisol, together with decreased glucocorticoid receptor sensitivity and disturbed feedback mechanisms, has been reliably observed in patients with MD. 66 Moreover, functional interactions between serotonergic and neurotrophic systems, both implicated in the pathogenesis and treatment of MD, 67 have also been reported. 68 In addition, polymorphisms in corticoid receptors have been shown to be related to antidepressant treatment outcome. 69, 70 Moreover, variants in genes encoding for the pathways in monoaminergic systems have been involved in this trait. 8 Thus, it may be of interest to explore the interactions of BDNF, glucocorticoid receptors and monoaminergic pathways polymorphisms in antidepressant treatment outcome.
The strength of our study consists of the use of a clinically well-defined and characterized large sample of patients with MD, without any other comorbid psychiatric condition. Differences in response to antidepressant drugs in major depressive episodes can be due to series of confounding variables, so we considered a wide range of clinical factors that may influence treatment response (such as sex, current age, age at onset, depression subtype based on disorder polarity (unipolar vs bipolar), occurrence of psychotic features during depressive episodes, severity of depression, number of previous depressive episodes and VRF) together with genotypes in a regression analysis, in order to best estimate the adjusted effect of the SNPs. Population stratification could be a confounding factor in case-control genetic studies. On account of this, we tested this possibility and evidence of stratification was not detected, suggesting that population stratification does not introduce significant bias into our analyses.
The study performed here has, however, some limitations. First, the control sample was not screened for mental disorders, but since the subjects were blood donors who are not allowed to take psychotropic medication, it is unlikely that depression cases are included in the control sample. Second, as the control individuals are a sample of healthy blood donors from the general population, they are not matching on sex and age with patients. Since depression is known to be more frequent in women than in men, we have introduced sex as a covariate in multivariate analysis to avoid this confounding factor in case-control analyses. The age of collection distribution differed between cases and controls, with the mean age of the controls being substantially lower; thus, it may be possible that some individuals in the control group will develop depressive disorders later in life; however, there are no significant differences between the mean age of the controls and the mean age at onset of the illness in the patients. Third, the sample contains depressives with both recurrent and single episodes, and the mixture of these conditions may introduce a bias in case-control designs regarding the interpretation of the role of a genetic factor in disease occurrence with the role in disease duration or tendency to recurrences; nevertheless we have analyzed both groups separately in our sample, without finding association with BDNF genotypes. Finally, some clinical data, such as age at onset of first affective episode, previous episodes, history of previous treatments and presence or absence of VRF were obtained retrospectively through a direct interview based on self-report data and medical records, so a recall bias cannot be ruled out.
In summary, the results reported here do not support a direct role of BDNF variants in the vulnerability to MD, but they support the implication of BDNF in the therapeutic response to antidepressants. Our results underline the importance of conducting large prospective pharmacogenetic therapeutic trials to test the role of neurotrophins in the therapeutic response in MD and their interactions with other genes involved in antidepressant drug efficacy.
Materials and methods
Subjects and clinical assessment
For an evaluation of association between BDNF and MD, we used a sample of unrelated patients consecutively recruited from the Mood Disorders Clinical and Research Unit of the Psychiatry Department at the 'Hospital Universitari de Bellvitge', who were in follow up, with visits usually every 2 months. All the patients were Caucasoid of Spanish origin for at least two generations. In total, we investigated 374 patients and 342 control subjects. The patients were diagnosed by experienced psychiatrists through structured interview 71 according to the Diagnostic and Statistical Manual of Mental Disorders IV criteria 72 for Mood Disorders (226 unipolar major depressive disorder, 148 BD). Control individuals were group matched to cases for ethnicity from blood donors recruited from the Blood and Tissue Bank from the Catalan Health Service.
The inclusion criteria were to have required antidepressant treatment for major depressive episode with a minimum score of 18 on the Hamilton rating scale for depression (HAM-D) and have no additional lifetime psychiatric diagnosis other than MD. Two experienced psychiatrists who independently examined all clinical material carried out patient recruitment. In case of doubt or disagreement, a third psychiatrist was involved in the decision, which was achieved by consensus. The cases were recruited from outpatient (42.5%) and inpatient (57.5%) sections of our clinic, the latter ones being followed up at the outpatient section after discharge. The severity of depression was assessed using the 21 item HAM-D, 73 and the first episode treated in our clinic, which fulfilled inclusion criteria was considered as index for the study. Other clinical variables such as age at onset, previous episodes and treatments and presence of VRF were obtained by means of an interview conducted in person supported by available medical information.
Based on previous studies, 74 data on the presence or absence of hypertension, diabetes mellitus, hypercholesterolemia, cigarette smoking, atrial fibrillation and evidence of vascular disease were summed into a composite of VRF; the presence of two or more VRF was designated as high vascular risk and the remaining characterized as low vascular risk.
This is a naturalistic pharmacogenetic study and all individuals were treated according to their psychiatrist's choice. Individuals who were admitted on single antidepressant medication were continued on it, with optimizing dosage if necessary, until at least 6 weeks were completed. Treatment outcome phenotype was defined according to Thase and Rush staging scheme that has been developed to assess resistance of antidepressant treatment. 2, 75 Assessment of treatment response with this method has already been used in previous studies. 76, 77 Patients were allocated to one of the following two groups: those from stage '0' (patients with history of sustained clinical remission considered as HAM-D21o7 at least during 2 months after major depressive episode treated with adequate trial of a single antidepressant at the first attempt) were considered 'remitters' and the remainder (stages 1-5) were considered 'nonremitters'.
The ethical review boards of the corresponding recruitment centers approved the study. All subjects, both cases and controls, provided written informed consent to participate.
Sample power calculation
Power calculations used Quanto Version 1.1 78, 79 to determine that the case-control sample had 92% power to detect a risk allele with 10% frequency, with an additive genotype relative risk of 2.0.
TagSNP selection
From the HapMap project data set, we utilized genotypes from the public release 16 (phase I data freeze; dbSNP b124) corresponding to the 60 individuals from the CEPH-30 -trios of European descent (http://www.hapmap.org). For that phase, in an 87.2 kb region containing the BDNF gene, the HapMap Project genotyped 27 SNPs; only SNPs having a unique mapping location on the NCBI B34 assembly and a minor allele frequency (MAF) higher than 10% were considered for further analysis (n ¼ 21; average spaced 4.36 kb). Bins of common SNPs in strong LD, as defined by r 2 higher than 0.85, were identified within this data set by using HapMap-LDSelect-Processor, which uses the 'LD Select' method 80 to process HapMap genotype dump format data corresponding to the locus region. Eight TagSNPs were selected for coverage of all bins: four SNPs were located in the 5 0 upstream region (rs12273363, rs908867, rs1491850 and rs1491851), one in the coding region (rs6265, corresponding to the functional Val66Met variant) and three in the 3 0 downstream region (rs11030096, rs925946 and rs10501087) (Figure 1 ).
Genotyping
SNPlex design and method. TagSNPs were genotyped using the SNPlex Genotyping System. SNPs that passed the design rules for the development of good assays were selected. In the case of the SNPlex system, which is a multiplexed assay format, these SNPs were mixed with other SNPs corresponding to different genes that are under study in our laboratory but were not considered in this particular analysis. For the genotyping process, we followed the manufacturer's protocol for the SNPlex Multiplex Genotyping Systems (Applied Biosystems, Foster City, CA, USA): 12 ml of each sample DNA at 75 ng/ml are fragmented by boiling at 991C for 10 min and 2 ml (150 ng) are allowed to dehydrate in a 384-well plate. For using custom multiplex pools (currently up to 48-plex), designed, synthesized and formulated by the manufacturer, the manufacturer's specifications are followed through phosphorylation, oligonucleotide ligation, exonuclease clean-up, PCR and hybridization steps (Applied Biosystems, Foster City, CA, USA). All reactions are set up in a 384-well format using various robotic systems. The high-throughput genotyping assays are performed at the genotyping facilities of CeGen, in the Barcelona Node ('Centro Nacional de Genotipado, Genoma España').
Genotyping for population admixture
To detect population admixture, a structured association method was used to further test each sample set for stratification between cases and controls. We selected 48 anonymous unlinked SNPs derived from a panel of 52 SNPs reported to be polymorphic in European, Asian and African populations, 81 which were genotyped by the SNPlex method (as described in the previous section). From our data, we retained for analysis only those SNPs in HWE with a genotyping rate 490% and with an r 2 o0.1. Thus, a total of 45 SNPs were used for these analyses. We used the computer program Structure 82 in an attempt to identify clusters of genetically similar individuals. This software implements a model-based clustering method using unlinked markers, where K populations are assumed, each characterized by a set of allelic frequencies. Then, based on simulation process, an estimation of the probability of K is obtained. To minimize bias effects from starting configuration, we set the burning length for the initial simulation process at 10 6 and a run length of 10 6 to get accurate parameter estimates. An admixture model with correlated frequencies was used, using five putative K values (1-5). Analysis was performed both with and without prior population information.
Additional genotyping of rs28383487
For determination of the functional C to A transversion occurring 281 bp upstream from the proposed transcription start site for exon 1, or in BDNF promoter, 55 rs28383487, we performed a pyrosequencing assay. The PCR was performed in 50 ml of PCR containing 50 ng of genomic DNA, 1 Â PCR buffer, 10 nmol dNTP, 1 U AmpliTaq Gold, 0.1 mmol MgCl2, 1 pmol of each forward and reverse primer and 29.8 ml distilled H 2 O. The PCR started with incubation at 951C for 9 min and then 35 repeated cycles of 951C for 30 s, 601C for 30 s, 721C for 30 s, finalizing after the cycles with 10 min at 721C. The primers used in the PCR were forward primer 5 0 -TAGTCTGCCGGCGCTGAT-3 0 and the biotinylated reverse primer 5 0 -CTGAATTCGGCTCGGGAGAT-3 0 . The nucleotide sequence was then identified by PyrosequencingTM as described, 83 using the PSQTM 96 System with PSQTM 96 SNP reagent kit according to the manufacturer's instructions (Pyrosequencing AB, Uppsala, Sweden). The primer used for pyrosequencing was 5 0 -AGCAACAAGTTCCCC-3 0 .
Statistical analysis
To better determine the real effect of SNPs on antidepressant treatment outcome, we first performed a logistic regression analysis including a wide range of clinical factors: sex, current age, age at onset, depression subtype based on disorder polarity (unipolar vs bipolar), occurrence of psychotic features during depressive episodes, severity of depression (HAM-D scores), number of previous depressive episodes and VRF (high vs low vascular risk). Using a stepwise procedure, we obtained the following statistically significant variables: current age, age at onset, unipolar or bipolar depression and HAM-D scores. We searched and tested all interactions between them using likelihood ratio tests. Only interaction between depression subtype based on disorder polarity and HAM-D scores remained significant. Therefore, this interaction was also added to the final model. Each polymorphism was tested in controls to ensure the fitting with HWE. To assess the genetic effect of the SNPs, multivariate methods based on logistic regression analyses were used. We estimated the crude OR and their 95% CI. We then estimated the OR adjusted by those clinical variables that were selected in the stepwise procedure.
The SNP effects were analyzed under a codominant model (three separated genotypes). We also fitted a dominant model (heterozygotes grouped with the homozygotes for the rare allele) a recessive model (heterozygotes grouped with the homozygotes for the common allele) an overdominant model (homozygotes grouped) and an additive model (three genotypes as a quantitative variable). The best model was selected using the Akaike information criterion. These analyses were performed using the SNPassoc R package. 84 Bonferroni correction for eight independent tests was applied.
All haplotype frequencies were estimated using the expectation maximization (EM) algorithm in haplo.stats in the R programming language, 85 a generalized linear regression framework that incorporates haplotype phase uncertainty by inferring a probability matrix of haplotype likelihoods. In addition, we used a sliding window technique to fine map any potential signals within the region using also the haplo.stats R package. The size of the window varied from two, three and four SNPs in order to provide a comprehensive assessment of the haplotype subsets within the gene. Furthermore, the permutation procedure was used to estimate the significance of the best result from the two, three, and four marker sliding window analyses, and one thousand permutations were performed in each permutation analysis.
The robustness of these individual findings was investigated by a bootstrap analysis. The bootstrap approach selects random samples of size n (n1 cases þ n2 controls) drawn from the original data set. 86 Through the repetition of the sampling procedure, the association between each of the polymorphisms and treatment outcome phenotype was determined and information was obtained on the variability and validity of the parameter estimate. We repeated the selection procedure on 300 bootstrap data sets generated from the original sample and we reported the number of times that a particular association was statistically significant (at Bonferroni significant level) between each polymorphism and the phenotype.
